Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2010-019064-36
    Sponsor's Protocol Code Number:MA-PY-Hp09-01
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-06-19
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2010-019064-36
    A.3Full title of the trial
    Efficacy and Safety of PYLERA™ (Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride) With Omeprazole Given x 10 Days in Subjects Who Failed Treatment for Eradication of Helicobacter pylori
    Efficacia e sicurezza della somministrazione di PYLERA` (bismuto subcitrato potassio, metronidazolo e tetraciclina cloridrato) con omeprazolo per un periodo di 10 giorni in soggetti refrattari a trattamenti di eradicazione dell'Helicobacter pylori
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy and Safety of PYLERA™ (Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride) With Omeprazole Given x 10 Days in Subjects Who Failed Treatment for Eradication of Helicobacter pylori
    Efficacia e sicurezza della somministrazione di PYLERA™ (bismuto subcitrato potassio, metronidazolo e tetraciclina cloridrato) con omeprazolo per un periodo di 10 giorni in soggetti refrattari a trattamenti di eradicazione dell’Helicobacter pylori
    A.4.1Sponsor's protocol code numberMA-PY-Hp09-01
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAPTALIS PHARMA CANADA INC.
    B.1.3.4CountryCanada
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAptalis Pharma SAS
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAptalis Pharma SAS
    B.5.2Functional name of contact pointMr Gilles CHAUVIERE
    B.5.3 Address:
    B.5.3.1Street AddressRoute de Bû
    B.5.3.2Town/ cityHoudan
    B.5.3.3Post code78550
    B.5.3.4CountryFrance
    B.5.4Telephone number33 1 30461900
    B.5.5Fax number33 1 30596547
    B.5.6E-mailgchauviere@aptalispharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name PYLERA
    D.2.1.1.2Name of the Marketing Authorisation holderAptalis Pharma US Inc.
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTETRACYCLINE HYDROCHLORIDE
    D.3.9.1CAS number 64-75-5
    D.3.9.4EV Substance CodeSUB04760MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number125
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMETRONIDAZOLE
    D.3.9.1CAS number 443-48-1
    D.3.9.4EV Substance CodeSUB08922MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number125
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBISMUTH SUBCITRATE POTASSIUM
    D.3.9.1CAS number 880149-29-16
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number140
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product Yes
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name LOSEC
    D.2.1.1.2Name of the Marketing Authorisation holderAstraZeneca UK Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOMEPRAZOLE
    D.3.9.1CAS number 73590-58-6
    D.3.9.4EV Substance CodeSUB09439MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Eradication of Helicobacter pylori
    Eradicazione dell’Helicobacter pylori
    E.1.1.1Medical condition in easily understood language
    Eradication of Helicobacter pylori
    Eradicazione dell’Helicobacter pylori
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level SOC
    E.1.2Classification code 10021881
    E.1.2Term Infections and infestations
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the rate of Helicobacter pylori (H. pylori) eradication following quadruple therapy with bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride, given with omeprazole in H. pylori infected subjects, who failed one course of omeprazoleamoxicillin- clarithromycin (OAC) eradication therapy
    Valutare il tasso di eradicazione dell’Helicobacter pylori (H. pylori) a seguito di terapia quadrupla con bismuto subcitrato potassio, metronidazolo e tetraciclina cloridrato somministrati insieme a omeprazolo in pazienti con infezione da H. pylori risultati refrattari a un ciclo di terapia di eradicazione basata su omeprazolo-amoxicillina-claritromicina (OAC).
    E.2.2Secondary objectives of the trial
    1. To evaluate the effect of antibiotic resistance of H. pylori on the efficacy of treatment with PYLERA™. 2. To assess the safety and tolerability of this therapeutic regimen with respect to subject-reported and investigator-observed adverse events, and clinical laboratory abnormalities. 3. To compare eradication outcomes in subjects with presence/past history of peptic ulcers at baseline versus those without. 4. To assess compliance to treatment. 5. To identify potential treatment success drivers in OAC-refractory subjects, including age, in vitro resistance, type and number of treatments, and comorbidities. 6. To evaluate resource utilization associated with treatment failure from three months prior to baseline.
    1.Valutare l’effetto dell’antibiotico-resistenza dimostrata da H.pylori sull’efficacia del trattamento con PYLERA™.2.Determinare la sicurezza e la tollerabilita' di questo regime terapeutico in relazione agli eventi avversi riferiti dal soggetto e osservati dallo sperimentatore,nonche' alle anomalie delle analisi cliniche di laboratorio.3.Confrontare gli esiti dell’eradicazione fra soggetti con storia attuale/pregressa di ulcera peptica al basale e soggetti esenti da tale patologia.4.Determinare la compliance al trattamento.5.Individuare potenziali fattori di successo del trattamento in soggetti refrattari alla terapia OAC come l’eta',la resistenza in vitro,la natura e la quantita' dei trattamenti e la presenza di comorbilita'.6.Valutare l’uso di risorse associato al fallimento della terapia nei tre mesi precedenti al basale.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Men or non-pregnant, non-nursing women, 18 years of age and older. 2. Women of childbearing potential must use a medically acceptable birth control method for the duration of the study (i.e. from Screening) and for 30 days thereafter. Women who are not of childbearing potential will be defined as postmenopausal (no presence of menses for at least 12 months if > 50 years of age, or no presence of menses for 24 months if . 50 years of age), surgically sterilized (tubal ligation for at least 6 months, ovariectomy or hysterectomy) or diagnosed infertile. 3. Positive for H. pylori status using both 13C-urea breath test (UBT) and rapid urease test (RUT). 4. Eradication failure to one prior course of OAC treatment, one prior course of OAC treatment and one supplemental treatment, or one prior course of OAC treatment and two supplemental treatments. 5. Presence of upper gastrointestinal symptoms. 6. Mental and legal ability to give written informed consent.
    1. Maschio o femmina non in stato di gravidanza e non in fase di allattamento, con eta' minima di 18 anni. 2. Le donne in eta' fertile devono utilizzare un metodo di contraccezione clinicamente accettabile per tutta la durata dello studio (ovvero a partire dallo screening) e per i 30 giorni successivi. Le donne in eta' non fertile saranno definite come pazienti in eta' postmenopausale (assenza di mestruazioni da almeno 12 mesi in caso di eta' &gt; 50 anni o assenza di mestruazioni da 24 mesi in caso di eta' ≤ 50 anni), sterilizzate chirurgicamente (legatura delle tube da almeno 6 mesi, ovariectomia o isterectomia) oppure con diagnosi di infertilita'. 3. Positivita' per H. pylori sia al test del respiro (urea breath test, UBT) con urea C13 sia al test rapido all’ureasi (rapid ureasi test, RUT). 4. Fallimento dell’eradicazione con un precedente ciclo di terapia OAC, con un precedente ciclo di terapia OAC e un trattamento supplementare, oppure con un precedente ciclo di terapia OAC e due trattamenti supplementari. 5. Presenza di sintomi gastrointestinali superiori. 6. Capacita' mentale e legale di rilasciare il consenso informato scritto.
    E.4Principal exclusion criteria
    1. Previous use of bismuth, metronidazole, and tetracycline combination therapy for H. pylori eradication 2. Previous surgery of the upper gastrointestinal tract (except cholecystectomy) 3. Presence or history of clinically significant impairment of renal function, hepatic function, or liver disease 4. Current or past medical history of severe or unstable cardiovascular, pulmonary or endocrine disease 5. Current or past medical history of Zollinger Ellison Syndrome 6. Any current or recent (within 1 month of screening) hematemesis, melena, or documented gastrointestinal bleeding, or clinically significant iron-deficiency anaemia 7. Malignant disease of any kind except for successfully treated skin cancer (basal or squamous cell) during the previous 5 years 8. Barrett’s esophagus or high-grade dysplasia 9. Dysphagia or vomiting as major symptoms 10. Drug, alcohol, or medication abuse within the past year 11. Continuous use of anti-ulcer drugs, including H2-receptor antagonists, sucralfate, and prostaglandins during the 2 weeks preceding the 13C-UBT at Screening 12. Continuous use of proton pump inhibitors (PPI) in the 2 weeks preceding the 13C-UBT at Screening 13. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) except acetyl-salicylic acid 100 mg or less daily 14. Requirement for anticoagulants/platelet aggregation inhibitors except for cardiovascular disease prevention (for example acetylsalicylic acid at a dose not exceeding 100 mg daily) and systemic glucocorticoids (due to the association with ulcer disease) 15. Use of systemic antibiotics in the 30 days prior to screening 16. Regular use (> 3 times per week) of bismuth compounds in the 30 days prior to screening 17. Presence of a contraindication or hypersensitivity to the use of any of the active ingredients or excipients contained within the provided study medications: omeprazole: subjects with rare hereditary problems of galactose intolerance, Lapp Lactase deficiency, glucose-galactose malabsoption bismuth metronidazole: active neurological disorder, history of blood dyscrasia, uncorrected hypothyroidism, uncorrected hypoadrenalism, alcoholism, concomitant use of disulfiram or use of disulfiram within the previous two weeks (can cause psychotic reactions) tetracycline Maalox Plus: subjects with rare hereditary problems of fructose intolerance 18. Use of any experimental drug or experimental device within the 90 days prior to screening and throughout the entire study 19. Known hypersensitivity to or previous adverse experience(s) with citric acid or any of the study medications 20. Subject known to be positive for human immunodeficiency virus (HIV), hepatitis, or other diseases transmissible by blood or biopsy samples 21. Any concern by the Investigator regarding the safe participation of the subject in the study or for any other reason the Investigator considers the subject inappropriate for participation in the study
    1. Precedente adozione di una terapia di combinazione a base di bismuto, metronidazolo e tetraciclina per l’eradicazione di H. pilori. 2. Precedente intervento chirurgico a carico del tratto gastrointestinale superiore (esclusa colecistectomia). 3. Presenza o anamnesi di insufficienza clinicamente significativa della funzione renale, della funzione epatica o epatopatia. 4. Presenza o anamnesi di malattia cardiovascolare, polmonare o endocrina grave o instabile. 5. Presenza o anamnesi di sindrome di Zollinger-Ellison. 6. Qualsiasi ematemesi, melena o emorragia gastrointestinale documentata, sia in corso che recente (entro 1 mese dallo screening), o anemia da deficienza di ferro di rilevanza clinica. 7. Patologia maligna di qualsiasi tipo, ad esclusione del cancro cutaneo (basocellulare o squamocellulare) trattato con successo nel corso dei 5 anni precedenti. 8. Esofago di Barrett o displasia di alto grado. 9. Disfagia o vomito quali sintomi principali. 10. Abuso di droghe, alcol o medicinali nel corso dell’ultimo anno. 11. Uso continuo di farmaci antiulcera, compresi antagonisti dei recettori H2, sucralfato e prostaglandine nel corso delle 2 settimane precedenti l’UBT C13 allo screening. 12. Uso continuo di PPI nelle 2 settimane precedenti l’UBT C13 allo screening. 13. Uso cronico di farmaci antinfiammatori non steroidei (FANS), ad eccezione di acido acetilsalicilico a dosi non superiori a 100 mg/die. 14. Necessario ricorso ad anticoagulanti/inibitori dell’aggregazione piastrinica per la prevenzione di malattie cardiovascolari (per es. acido acetilsalicilico a dosi non superiori a 100 mg/die) e glucocorticoidi per via sistemica (in quanto associati a ulcera). 15. Uso di antibiotici per via sistemica nei 30 giorni precedenti lo screening. 16. Uso regolare (&gt; 3 volte alla settimana) di composti di bismuto nei 30 giorni precedenti lo screening. 17. Presenza di controindicazioni o ipersensibilita' all’uso di uno qualsiasi dei principi attivi o degli eccipienti contenuti nei farmaci forniti nell’ambito dello studio: omeprazolo: soggetti con rari problemi ereditari di intolleranza al galattosio, deficit di Lapp lattasi, malassorbimento di glucosio-galattosio bismuto metronidazolo:- disturbi neurologici in fase attiva, storia di discrasie ematiche, ipotiroidismo non corretto, iposurrenalismo non corretto, uso concomitante di disulfiram o uso di disulfiram nelle due settimane precedenti (possibilita' di reazioni psicotiche) tetraciclina Maalox Plus: soggetti con rari problemi ereditari di intolleranza al fruttosio 18. Uso di farmaci sperimentali o dispositivi sperimentali nei 90 giorni precedenti lo screening e per l’intera durata dello studio. 19. Ipersensibilita' nota all’acido citrico o ad uno dei farmaci oggetto dello studio, o precedente/i esperienza/e avversa/e con essi. 20. Soggetto con positivita' nota al virus dell’immunodeficienza umana (HIV), dell’epatite o di altre malattie trasmissibili per via ematica o per mezzo di campioni bioptici. 21. Eventuali preoccupazioni da parte dello Sperimentatore riguardanti la partecipazione sicura del soggetto allo studio o per qualsiasi altro motivo lo Sperimentatore consideri il soggetto inadeguato a partecipare allo studio.
    E.5 End points
    E.5.1Primary end point(s)
    Eradication rate, defined as one negative 13C-UBT performed at least 28 days post treatment.
    Tasso di eradicazione definito come negativita' all’UBT C13 eseguito almeno 28 giorni dopo la fine del trattamento.
    E.5.1.1Timepoint(s) of evaluation of this end point
    at least 28 days post treatment.
    almeno 28 giorni dopo il trattamento.
    E.5.2Secondary end point(s)
    1. Subgroup analysis evaluating H. pylori eradication rate in subjects with antibiotic-resistant strains of H. pylori. 2. Subgroup analysis evaluating H. pylori eradication rate in subjects with presence/history of peptic ulcer versus those without.
    1. Analisi di sottogruppo per valutare il tasso di eradicazione di H. pylori in soggetti con ceppi di H. pylori antibiotico-resistenti. 2. Analisi di sottogruppo per valutare il tasso di eradicazione di H. pylori in soggetti con presenza/storia di ulcera peptica rispetto a soggetti esenti da tale patologia.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Post-study analysis
    Analisi post-studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA13
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last visit Last subject
    Last visit Last subject
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 35
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 15
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 50
    F.4.2.2In the whole clinical trial 50
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There are no specific treatment or care planned after the subject has
    ended the participation in the trial.
    Non ci sono specifici trattamenti o cure pianificati dopo che il soggetto ha terminato la partecipazione allo studio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-06-15
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-04-17
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 18:13:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA